Rockwell Medical Enters into 3-Year Product Purchase Agreement with Sanderling Renal Services; Expands Distribution Capabilities Westward into Utah
September 28 2023 - 6:00AM
Business Wire
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that the Company entered into
a three-year product purchase agreement with Sanderling Renal
Services, Inc. ("Sanderling"), a full-service provider of
in-center, home dialysis and renal telemedicine services focusing
on patients in rural and underserved communities across the United
States.
Under the terms of this agreement, which includes supply and
purchasing commitments and has the potential to generate millions
of dollars in net sales for Rockwell Medical over the course of the
contract, Rockwell Medical will be the preferred supplier of liquid
and dry acid and bicarbonate hemodialysis concentrates to
Sanderling's facilities located throughout California, Colorado,
Nevada, Oklahoma, Tennessee, Illinois, and Utah. In addition to
supplying hemodialysis concentrates and concentrates accessories,
Rockwell Medical will also provide Sanderling with its DAMX45 Dry
Acid Concentrate Mixer units to support Sanderling's preference to
conveniently mix acid concentrate on-site.
"Sanderling provides in-center and home-based dialysis out of
clinics that are located in USDA-defined rural areas with limited
access to healthcare resources," said Dr. Jerome Tannenbaum,
Founding Chairman and CEO of Sanderling. "We continue to look to
expand our services in existing markets while moving into new
communities to broaden our access to dialysis patients through our
telemedicine and eDialysis offerings. Hemodialysis concentrates are
critical to vulnerable patients with ESKD. Partnering with Rockwell
Medical ensures that we are able to provide our clinics and their
patients with the highest quality products supported by the best
customer service in the industry."
"Sanderling is renowned for bringing high-quality medical
services to communities with limited access to healthcare sources,"
said Tim Chole, Senior Vice President, Sales and Marketing at
Rockwell Medical. "We are proud to partner with Sanderling and
support its innovative approach to the care of end-stage kidney
disease patients in rural and other underserved populations."
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that
enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and
provide a positive impact on the lives of hemodialysis patients.
Hemodialysis is the most common form of end-stage kidney disease
treatment and is typically performed at freestanding outpatient
dialysis centers, hospital-based outpatient centers, skilled
nursing facilities, or in a patient’s home. Rockwell Medical's
products are vital to vulnerable patients with end-stage kidney
disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second
largest supplier of acid and bicarbonate concentrates for dialysis
patients in the United States and intends to become the leading
global supplier of hemodialysis concentrates. Certified as a Great
Place to Work® in 2023, Rockwell Medical is Driven to Deliver
Life-Sustaining Dialysis SolutionsTM. For more information, visit
www.RockwellMed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident," “are determined,” “are on track,” “are resolute in our
vision,” "work to," "drive towards," “focused on,” or the negative
of these terms, and similar expressions, or statements regarding
intent, belief, or current expectations, are forward looking
statements. There can be no assurance that Rockwell Medical will
become the leading global supplier of hemodialysis concentrates or
will generate the expected revenue from its contracts. While
Rockwell Medical believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical's SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include, but are not limited to those risks more fully discussed in
the "Risk Factors" section of our Annual Report on Form 10-K for
the year ended December 31, 2022, as such description may be
amended or updated in any future reports we file with the SEC.
Rockwell Medical expressly disclaims any obligation to update our
forward-looking statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230928227856/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024